Avalon GloboCare Corp. (ALBT) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] Avalon Globocare Corp (ALBT) 3-Minute Overview > **💡 One-Sentence Summary** > > Avalon Globocare is a micro-cap “story stock” trying to pivot into consumer diagnostics and generative-AI video software, but currently bleeding cash and financially very fragile. > **📍 Basic Profile** > > Market Cap **$2.3 million** · Diversified diagnostics & AI software (classified as Real Estate by data vendor, but functionally healthcare/AI micro-cap) · NASDAQ · Price **$1.09** --- > **⚡ 3 Things You Should Know** > > 1. ⚠️ Extremely weak finances: Negative ROE (~‑138%), huge negative margins, and a current ratio of **0.15** basically say “cash crunch risk,” meaning they could need frequent capital raises or face going-concern issues. > > 2. 📉 No growth yet, just a pivot story: Multi-year revenue growth is sharply negative (‑138% over 3Y, ‑297% over 5Y), so this is not a scaling business today—it’s a small company trying to reinvent itself around KetoAir diagnostic devices and generative-AI video platforms. > > 3. 🎲 Pure speculation territory: Trading at **~0.5x book** and **P/S ~1.7x** with no PE (loss-making), plus recent news buzz (AI partnership with AMD, new AI patents, Nasdaq compliance regained) means the stock can move violently on headlines, but the fundamental risk is very high. --- > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-------------------|-----------------|---------| > | Profitability | Weak👎 | Net margin **‑1355%**, ROE ≈ **‑138%** – heavy losses on a tiny equity base | > | Growth Rate | Slow🐢 / Negative | 3Y and 5Y revenue growth deeply negative – shrinking, not growing | > | Financial Health | Tight🧡 | Current ratio **0.15**, quick ratio **0.22**, debt-to-equity **~1.1** – liquidity stress | > | Valuation | Cheap-looking | PE N/A (losses), **P/S ~1.7x**, **P/B ~0.5x** – but reflects high risk more than hidden bargain | --- ## 📋 Layer 2: 2-Minute Deep Dive ### 📊 How Does This Company Make Money? **Business Model in One Sentence:** Sells and distributes niche precision diagnostic consumer devices (like the KetoAir breath analyzer) and is building SaaS-style generative-AI video/commentary platforms, aiming to earn from hardware sales, software subscriptions, and possibly B2B licensing. **Revenue Breakdown (inferred from news, not exact percentages):** | Business | Share | Trend | Comment | |-----------------------------------------------------------------|-------|-------|---------| | Precision diagnostic consumer products (e.g., KetoAir) | [Data unavailable] | →/↑? | FDA-registered device; marketing and distribution focus, but scale is still tiny. | | Generative AI video & publishing software (Avalon Quantum / RPM Interactive / Catch-Up platform) | [Data unavailable] | ↑ (early) | New AI video commentary and short-form video SaaS platforms; currently more of a development/early commercialization story than a proven revenue engine. | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |----------------|-------------:|----------------|----------------| | Gross Margin | **25.7%** | Below average | Decent but not amazing for a software/diagnostic mix; suggests small scale and limited pricing power. | | Net Margin | **‑1355%** | Very bottom | For every $1 of sales they’re losing more than $13 – classic micro-cap, early-stage / distressed profile. | | ROE | **‑137.6%** | 🚨Extremely poor | Equity is being eroded quickly; indicates either big write-downs, high expenses, or both on a small capital base. | --- ### 📈 How's the Growth? **Growth Assessment:** **Slowing / Shrinking** | Metric | Latest | vs Last Years | Trend | |------------------|-----------|---------------|-----------| | Revenue Growth 3Y| **‑138%** | N/A detail | Severe contraction | | Revenue Growth 5Y| **‑297%** | N/A detail | Long-term decline | | EPS Growth 3Y/5Y | N/A | N/A | Company remains loss-making, data not provided | **Growth Quality:** This isn’t a “hyper-growth stock” yet; it’s more like a turnaround/pivot. Revenue has shrunk sharply over 3–5 years, suggesting legacy business lines failed or were scaled back. The new growth story (KetoAir + generative-AI video tools) is just starting and not yet visible as strong numbers. Any “growth” in the near term is likely to come from a low base and could be overshadowed by dilution or ongoing operating losses. --- ### 💰 Financial Health Check **One Sentence:** Think of a person with almost no savings, credit card balances close to their income, and spending far more than they earn—short-term cash pressure is the big story. | Metric | Value | Safe Zone | Assessment | |----------------------------|-----------|-----------------|----------------| | Debt-to-Equity | **1.10** | <0.6 preferable | ⚠️High – leveraged for such a tiny, loss-making firm | | Long-Term Debt-to-Equity | **0** | <0.6 | ✅No long-term debt (good), but doesn’t solve liquidity issues | | Current Ratio (quarterly) | **0.15** | >1.5 healthy | 🚨Dangerous – current liabilities far exceed current assets | | Quick Ratio (annual) | **0.22** | >1.0 healthy | 🚨Dangerous – cash + near-cash barely cover a fraction of short-term obligations | | Interest Coverage | **‑1.7x** | >3x comfortable | 🚨Negative – can’t cover interest from operating earnings | | Cash Flow per Share (TTM) | **‑0.90** | >0 | 🚨Negative – burning cash | In other words, without fresh financing (equity raises, debt, or deals), the balance sheet is under real stress. That’s why micro-caps like this often do repeated offerings, reverse splits, or asset sales. --- ### 🏷️ Is It Expensive Now? **Price Position (52-week range):** - 52-Week Low: **$0.42** - 52-Week High: **$11.66** - Current: **$1.09** Position within range: - Range width = 11.66 – 0.42 = 11.24 - Distance from low = 1.09 – 0.42 = 0.67 - Position ≈ **6%** of 52-week range → **Near the low** | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|-----------:|----------:|------------:| | Criteria | 0–33% | 33–66% | 66–100% | | **Current** | ● (~6%) | | | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |------------------|------------------|------------------------|-----------| | vs Own History | PE: N/A (losses) | 5-year avg: N/A | Not meaningful – no stable profits. | | vs Book Value | **P/B ~0.5x** | 1x = “book value” | Market pricing it at a big discount to accounting equity, typical for distressed micro-caps. | | vs Sales (TTM) | **P/S ~1.66x** | Many small med/AI 2–5x | Not crazy on sales, but risk-adjusted it’s not “obviously cheap.” | **What the Current Valuation is Betting On:** The market is basically saying: “We’ll give you a modest multiple on your tiny revenue and a discount to book, but we’re not paying up until you show real traction and fix the balance sheet.” Any big upside from here likely depends on: - Successful commercialization of the **KetoAir** device in B2B and B2C channels. - Monetization of **AI video commentary and short-form video SaaS platforms** (Avalon Quantum / RPM Interactive / Catch-Up). - Ability to raise cash on acceptable terms without completely crushing existing shareholders. --- ### 📰 Any Recent News? | Date (approx) | Event | Impact | |---------------|-------|--------| | Feb 2026 | Joins **AMD AI Developer Program** to build next-gen video and automation tools. | **Positive** – strengthens AI narrative and tech credibility, but still early-stage, no guaranteed revenue. | | Jan 2026 | Subsidiary **Avalon Quantum AI** files U.S. provisional patents for AI-driven systems to generate personalized, compliance-ready automated commentary videos. | **Positive (narrative)** – builds IP pipeline and AI story; commercial impact uncertain and likely long-dated. | | Jan 2026 | **FDA establishment registration renewal** for KetoAir device; plans B2B/B2C launch via Catch-Up, its AI-powered short-form video SaaS platform. | **Positive** – regulatory footing for KetoAir plus a cross-over story between med devices and AI marketing. Execution risk remains. | | Jan 2026 | Company **regains Nasdaq equity compliance**, launches marketing for automated generative AI video platform. | **Positive but defensive** – avoids Nasdaq delisting for now; confirms prior financial stress and equity deficiency. | | Dec 2025 | Acquisition/spotlight of **RPM Interactive**, a generative AI automated video creation platform. | **Positive narrative** – bolsters AI angle and content tech; integration and monetization unknown. | | Dec 2025 | Insider Michael Mathews receives 1,365 shares (code “A” – typically an award). | Slight **positive** – modest insider alignment, but size is too small to be a strong signal. | --- ## 📊 Layer 3: 3-Minute Complete Analysis ### I. Detailed Financial Data (Some data points are incomplete, but we can sketch the direction.) **Profitability Trends (directional):** | Metric | This Period (TTM/latest) | 3-Year View | 3-Year Trend | |-------------|--------------------------|---------------------|--------------| | Gross Margin| **25.7%** | [Data unavailable] | Unclear, but not high for a “software + device” story. | | Net Margin | **‑1355%** | [Data unavailable] | Clearly very negative and likely has been negative throughout. | | ROE | **‑137.6%** | [Data unavailable] | Suggests persistent value destruction on equity. | **Growth Trends (directional):** | Metric | This Period | Last Year | Year Before | 3-Year Trend | |------------------|------------:|----------:|-----------:|-------------| | Revenue Growth | ‑138% (3Y) | N/A | N/A | Severe contraction, business has shrunk. | | Revenue Growth | ‑297% (5Y) | N/A | N/A | Decline over a longer horizon – not a young hypergrowth story. | | EPS Growth | N/A | N/A | N/A | Still loss-making, so growth metrics are less meaningful. | Given one historical EPS data point: - 2023-09-30 EPS: **‑$0.14** (no analyst estimate) So there isn’t even much Wall Street coverage – typical for a micro-cap. --- ### II. Earnings Track Record **Last Reported Quarter vs Expectations:** | Quarter End | EPS Expected | EPS Actual | Surprise | |---------------|-------------:|-----------:|---------| | 2023-09-30 | N/A | **‑0.14** | N/A – no consensus | **Earnings Trend Interpretation:** - No consistent analyst coverage; this is under the radar of large institutions. - Losses per share are still there; given the tiny market cap, any further capital raise tends to be dilutive. - Without positive and growing EPS, the stock trades far more on sentiment and news (AI deals, patents, Nasdaq compliance) than on fundamentals. --- ### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |------------------|------:|-----------:| | Strong Buy/Buy | 0 | 0% | | Hold | 0 | 0% | | Sell | 0 | 0% | No published recommendations in the dataset – essentially **no mainstream analyst coverage**. **Target Price:** N/A **vs Current Price:** N/A – no formal upside/downside consensus. **Insider Activity (recent):** - **Michael Mathews** (director/CEO of RPM Interactive) – received **1,365 shares** on 2025-12-12 (code “A,” usually stock award or grant). > Insider awards like this are a mild positive for alignment but not a strong “insiders are buying aggressively” signal. A serious bullish insider signal would usually be open-market purchases with significant dollar value relative to market cap. --- ### IV. Key Risk Alerts 1. **Liquidity & Going Concern Risk:** - Ultra-low current ratio (~0.15) and quick ratio (~0.22), negative cash flow per share, and negative interest coverage all scream **cash stress**. → If they can’t raise capital or improve cash flow quickly, they may face severe dilution, restructuring, or even survival risk. 2. **Execution Risk on New Business Model (AI + Diagnostics):** - The company is trying to pivot into AI-driven video software and consumer diagnostics (KetoAir, Catch-Up, RPM Interactive, Avalon Quantum AI). None of this is yet proven at scale. → If the AI platforms don’t gain real paying users and the KetoAir device doesn’t see strong adoption, the “story” may never translate into sustainable revenue. 3. **Micro-Cap Volatility & Corporate Actions:** - Market cap around **$2.3M**, large price swings (current ~6% above 52-week low, but far below 52-week high of $11.66), and a history involving Nasdaq compliance issues. → You should be prepared for sudden spikes and crashes, potential reverse splits, frequent equity offerings, and sensitivity to any negative news. --- ## 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** Avalon Globocare is an ultra-small NASDAQ-listed company trying to reinvent itself as a hybrid of precision diagnostic device distributor and generative-AI video software platform operator. > **Key strength:** Its strength is in the **optionality** of its new AI and diagnostics initiatives – AMD partnership, AI patents, and FDA-registered KetoAir give it a compelling story if execution and commercialization go right. > **Key risk:** The biggest concern is its **very weak financial position** and history of shrinking revenues, which make this less of a stable investment and more of a high-risk speculation where dilution and volatility are almost part of the package. --- > **🔍 Want to Learn More?** > > • Curious whether Avalon has any real “moat” or if it’s just riding the AI buzzwords? → Try **【Buffett Mode】** for a moat and business-quality deep dive. > • Worried about hidden landmines like future offerings, reverse splits, or legal issues? → Try **【Muddy Mode】** for focused risk screening. > • Thinking of it as a high-risk growth/turnaround bet and want to sanity-check potential upside vs dilution and failure risk? → Try **【Musk Mode】** for scenario-based growth valuation.